- Capital Cube•7 days ago
Click here to see latest analysisCapitalcube gives Neurocrine Biosciences, Inc. a score of 29.Our analysis is based on comparing Neurocrine Biosciences, Inc. with the following peers – Repligen Corporation, Repros Therapeutics Inc., Paratek Pharmaceuticals Inc, Palatin Technologies, Inc., Pfizer Inc., Eli Lilly and Company, AbbVie, Inc., CASI Pharmaceuticals Inc, ANI Pharmaceuticals, Inc. and Athersys, Inc. […] (Read more...) The post Neurocrine Biosciences, Inc. – Value Analysis (NASDAQ:NBIX) : July 20, 2016 appeared first on CapitalCube.
- Capital Cube•8 days agoNeurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016
Click here to see latest analysis*Disclaimer : This is as of previous day’s closing price.Technical IndicatorsBelow is a quick look at 5 technical indicators for Neurocrine Biosciences, Inc.. More studies are available on the Technical Chart.IndicatorSignalClosing Price above/below 50 Day Moving AverageBullishClosing Price above/below 200 Day Moving AverageBullish50 Day Moving Average above/below 200 Day Moving […] (Read more...) The post Neurocrine Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : NBIX-US : July 19, 2016 appeared first on CapitalCube.
Neurocrine Biosciences Inc.NasdaqGS
After hours: 49.620.00 (0.00%) as of 5:18 PM EDT
|Bid||38.12 x 100|
|52wk Range||31.25 - 58.46|
|Day's Range||49.16 - 50.05|
|Avg Vol (3m)||1,117,206|
As of 4:00 PM EDT. Market closed.